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Reply
The additional perspectives supplied by Peter Harris
and the other committee members of EUROSTAR in
their letter regarding my editorial1 are most welcome and
should convince the readers of the Journal of Vascular
Surgery that they have acted responsibly in reporting the
results of their registry.
I think they should be aware that, from previous con-
versations, I support EUROSTAR’s objectives and contin-
ue to look forward, both as a vascular surgeon and an edi-
tor, to the objective perspectives their reports are regularly
bringing to this field. I do not see the EUROSTAR inves-
tigators as part of the problem I was addressing but as
potential leaders in developing solutions. North American
trialists could well take a page from their book. Anything
that will produce the wider dissemination of objective out-
comes in this fast changing field, including the prompt
reporting of significant adverse events, is welcomed, as is
support of these efforts by industry, as long as it is without
inappropriate superimposed controls.
One point worthy of further comment is the importance
of reporting device-specific data. The EUROSTAR committee
believes that some “caution is justified with regard to direct
head-to-head comparison.” That may be true, but lumped
data of experiences with multiple devices are of limited value
if the data are not stratified for device. Caution indeed might
be needed if device-specific groups are not also compared
with regard to case severity and the factors known to affect
outcome to be sure apparent performance differences are
real. That has to do with proper reporting practices. Limited
early data from the learning curves of new devices can be
withheld from such comparisons until there are sufficient
numbers to avoid type II errors. I know the EUROSTAR has
been uncomfortable with this limitation on reporting device-
specific data and am pleased to see it changing.
A second important issue is what is the appropriate 
middle ground between “premature allegations of device fail-
ure” and significantly delayed disclosure, on which the
EUROSTAR investigators have clearly tried to tread. They
fear that the former extreme could expose researchers to
claims from manufacturers for compensation for commer-
cial damages and that professional advice may well be
appropriate before entering into research contracts. This
point is well taken and is one of the aspects dealt with by
myself and Dr Johnston in a broader commentary on 
the potential problems with industry-supported clinical
research, which will soon be published in this journal, so I
will not comment further on it, except to say that actions
strictly motivated by concern for patient safety would seem
unlikely to be held liable. One is more likely to be held liable
for not protecting patient safety.
In regard to specific problems not being identified by
device, it was stated that “we considered that the company
itself had the primary responsibility to disclose this informa-
tion to the professional world.” The companies do have this
responsibility, but clinical investigators have a responsibility
to the proper reporting of trial data. Also, patient safety is
their prime responsibility and it should be a central consid-
eration during the joint discussions, which are invariably
held between the principal investigators and the company
representatives when such problems are first discovered.
Charges of “premature allegations of device failure” are
unlikely to arise from such discussions. The company may
ask for discretion while more information is quickly gath-
ered, but some additional action seems to be appropriate if
multiple device-related complications of the same kind have
been observed, such as ending the enrollment of patients in
a trial or ending the marketing of the device so that it will
not be implanted in other patients before the likely cause
and seriousness of the complication is satisfactorily deter-
mined. Such cautious actions should not “unnecessarily
alarm” patients who already have the device, another of
their concerns, but it might protect patients who could be
future candidates for the device. Interestingly, the low-risk
limb of the US Vanguard trial was stopped at about the time
the information on the six fabric erosions was disclosed,
with the declaration of full enrollment.
Thirdly, I presume that it is from a sense of fairness that
the authors also defend Boston Scientific Corporation, but
that is unnecessary. I was eventually able to get in touch with
one of their representatives after the case report of a fabric
erosion in a Vanguard endograft, on manuscript revision,
revealed that there were actually six cases of erosion. Charles
Pierson of Boston Scientific Corporation kindly supplied me
with much additional perspective, some of which I was able
to insert at the galley proof stage of my editorial. So, I am
now privy to much of the information in your letter. The
issue remains whether such letters to its customers fulfills a
company’s responsibilities regarding the safety of the ulti-
mate customer of this device, the patient. Also at issue is how
adequately such communications between the company and
those who insert its devices will inform the vascular surgeons
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in the community, to whom a patient with abdominal aortic
aneurysm may present and who must decide between pro-
ceeding with open repair or referring the patient to one of
the endograft centers, and if so which one. I am not con-
vinced that this amounts to being “both timely and effective
in alerting the vascular community,” as you claim. Thus, I
am not willing to alter one of my closing statements that
such disclosure “does not diminish the awareness gap that
exists for much of the vascular community.”
I doubt that the EUROSTAR steering committee and
I differ significantly philosophically or in our goal to bring
full and complete information on these new abdominal
aortic aneurysm endograft devices to the vascular commu-
nity as quickly as possible. If some of the examples selected
in my editorial directed toward this goal have been taken
personally, as an attack on EUROSTAR, I hope my reply
reassures them that this was certainly not the intention.
Robert B. Rutherford
Senior Editor
Journal of Vascular Surgery
Silverthorne, Colo
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